All In Biotech

Drug Trial Radar · NCT05109611

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,389 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,389

Actual

Start

Nov 20, 2021

Primary completion

Jan 30, 2024

Study completion Apr 30, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection.

Conditions

  • SARS-CoV-2 Infection

Interventions

  • Nitric OxideDrug

    The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.

  • Nasal spray with isotonic salineDevice

    The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a COVID-19 Infection.Time frame: 28 days

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Medical Trust Clinics , Inc

    Oshawa, Ontario, Canada

  • National Institute of Infectious Diseases Hospital, Angoda

    Angoda, Sri Lanka

  • Karapitiya teaching Hospital,

    Galle, Sri Lanka

  • Peradeniya Teaching Hospital,

    Peradeniya, Sri Lanka

  • Puttalam Base Hospital,

    Puttalam, Sri Lanka

  • Colombo North Teaching Hospital,

    Ragama, Sri Lanka

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.